H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Celldex (NASDAQ:CLDX) Therapeutics Inc on Wednesday, setting a price target of $60, which is approximately 54.76% above the present share price of $38.77.
Pantginis expects Celldex Therapeutics Inc to post earnings per share (EPS) of -$0.45 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Celldex, with an average price target of $64.67.
The analysts price targets range from a high of $68 to a low of $60.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $153 thousand and a net profit of -$19.23 million. The company's market cap is $1.81 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.8% and a 30.71% success rate.
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.